Another milestone in the evolution of GLP-1-based diabetes therapies
- PMID: 34127851
- DOI: 10.1038/s41591-021-01394-7
Another milestone in the evolution of GLP-1-based diabetes therapies
Comment on
-
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.Nat Med. 2021 Jun;27(6):1079-1087. doi: 10.1038/s41591-021-01391-w. Epub 2021 Jun 14. Nat Med. 2021. PMID: 34127852 Clinical Trial.
References
-
- Parker, J. C. et al. J. Pept. Res. 52, 398–409 (1998). - DOI
-
- Saxena, A. R. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01391-w (2021). - DOI
-
- Sloop, K. W. et al. Diabetes 59, 3099–3107 (2010). - DOI
-
- Holst, J. J., Ørskov, C., Vagn-Nielsen, O. & Schwartz, T. W. FEBS Lett. 211, 169–174 (1987). - DOI
-
- Nauck, M. A. Metabolism 103, 154031 (2020). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical